Cyndi Lauper In this Cosentyx ad, however, Cyndi Lauper comes across as sincere and believable. She is one of three psoriasis sufferers in the vignette ad and her presence gets attention without being dominant.

Musician Cyndi Lauper was afraid to show her skin and speaks about how painful her psoriasis was. With the help of Cosentyx, she's been clear for over four years and doesn't really think about her skin condition anymore.

Novartis, Cyndi Lauper shine a light on psoriasis challenges in the workplace. Singer-songwriter Cyndi Lauper first joined Novartis' Cosentyx team as a spokesperson more than four years ago, and the two are still churning out initiatives.

COSENTYX TV Spot, 'Enough' Featuring Cyndi Lauper.

Secukinumab, sold under the brand name Cosentyx among others, is a human IgG1κ monoclonal antibody used for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It binds to the protein interleukin (IL)-17A and is marketed by Novartis.

Psoriasis affects many people in the U.S. - and that includes celebrities. Celebrities like Kim Kardashian, Jonathan Van Ness, Art Garfunkel, and Stacy London are some of the celebrities who have spoken out about their condition and how they have learned to manage it.

Bottoms of feet. More than half of people on COSENTYX were clear or almost clear on their scalp as early as 12 weeks compared to 6% taking placebo. Nail psoriasis improved by more than 46% in people receiving COSENTYX compared to an improvement of about 12% in people receiving placebo at week 16.

Secukinumab, sold under the brand name Cosentyx among others, is a human IgG1κ monoclonal antibody used for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis.

Cyndi Lauper Her psoriasis didn't appear until she was in her late 50s, but it came on with a vengeance. The award-winning singer and songwriter says it was so bad at times, she couldn't get out of bed. Stress management is a big part of her treatment program, along with an immune-altering drug.

Secukinumab is a drug that reduces the signs and symptoms of psoriatic arthritis, ankylosing spondylitis, and psoriasis. Secukinumab is commonly known as Cosentyx®.

COSENTYX is designed to target and block IL-17A, which is believed to play a role in inflammation that causes psoriasis plaques and joint pain in people with psoriatic arthritis.

Secukinumab, sold under the brand name Cosentyx among others, is a human IgG1κ monoclonal antibody used for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It binds to the protein interleukin (IL)-17A and is marketed by Novartis.